Enzalutamide in pts with nmCRPC after combined androgen blockade for recurrence following radical Tx in Japan (JCASTRE-zero) | ✅No restriction regarding PSADT ✅The changes in the survival curves of MFS and CFS were more gradual than that in PROSPER. https
Enzalutamide for M0CRPC after CAB following radical treatment. Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade … https://t.co/eQQ4kV7vNt #M0CRPC #nmCRPC #Enzalutamide
New article: Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with… https://t.co/Z2RDQXZ7mq #prostatecance